NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.54
-0.08 (-1.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.62
Open5.59
Bid0.00 x 1000
Ask0.00 x 1000
Day's Range5.40 - 5.69
52 Week Range4.64 - 51.60
Volume490,197
Avg. Volume777,865
Market Cap130.039M
Beta (3Y Monthly)2.59
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire17 days ago

    Novavax Provides Updates on the Global Pathways to Licensure for ResVax™

    Novavax, Inc. (NVAX) a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced updates on the pursuit of global licensure for ResVax™ following the Prepare™ Phase 3 clinical trial. The U.S. Food & Drug Administration (FDA) has recommended that Novavax conduct an additional Phase 3 clinical trial to confirm efficacy against medically significant RSV disease in infants born to mothers vaccinated with ResVax. Novavax has recently held meetings with several European national regulatory agencies to solicit input on the Prepare trial and possible pathways to licensure in Europe.  The next step will be to seek formal scientific advice this fall from the European Medicines Authority (EMA), the agency responsible for licensing vaccines for the European Union.

  • GlobeNewswire23 days ago

    Novavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Convention

    GAITHERSBURG, Md., June 04, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial.

  • GlobeNewswire2 months ago

    Novavax Announces Adjustment of Conversion Rate for its 3.75% Convertible Senior Notes due 2023

    GAITHERSBURG, Md., May 10, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes.

  • GlobeNewswire2 months ago

    Novavax Announces Reverse Stock Split of Common Stock

    Novavax, Inc. (NVAX) today announced it will effect a one-for-twenty reverse stock split of its issued and outstanding common stock. Stockholders of Novavax approved an amendment to Novavax’ Second Amended and Restated Certificate of Incorporation (the Amended Certificate) to effect the reverse stock split at a Special Meeting of Stockholders held on May 8, 2019. The reverse stock split is intended to give Novavax greater flexibility in considering and planning for future potential business needs and to increase the per share trading price of the Novavax’ common stock to enable Novavax to satisfy the minimum price requirement for continued listing on the Nasdaq Global Select Market.

  • GlobeNewswire2 months ago

    Novavax Announces Presentation of Phase 3 Data from RSV Maternal Immunization Program at 37th Annual Meeting of the European Society for Pediatric Infectious Diseases

    GAITHERSBURG, Md., May 01, 2019 -- Novavax, Inc. (NASDAQ: NVAX) today announced that Flor M. Muñoz, M.D., M.Sc., Associate Professor of Pediatrics Molecular Virology and.

  • GlobeNewswire2 months ago

    Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 2019

    GAITHERSBURG, Md., April 25, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2019 financial and operating results following the close of.

  • ACCESSWIRE2 months ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Novavax, Inc.

    NEW YORK, NY / ACCESSWIRE / April 12, 2019 / Levi & Korsinsky announces it has commenced an investigation of Novavax, Inc. (NASDAQ: NVAX) concerning possible breaches of fiduciary duty. To obtain additional ...

  • GlobeNewswire3 months ago

    Novavax Scientific Leadership to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD at World Vaccine Congress

    GAITHERSBURG, Md., April 09, 2019 -- Novavax, Inc. (NASDAQ: NVAX) today announced that Gregory M. Glenn, M.D., President of Research and Development, will share data from its.

  • ACCESSWIRE3 months ago

    Four Healthcare Stocks Picking Up Speed on Wednesday

    CORAL GABLES, FL / ACCESSWIRE / March 27, 2019 / The future of the healthcare stock market is directly correlated to whether companies in the healthcare sector have what it takes to meet the growing health challenges facing society. According to recent statistics, global shortages in primary care physicians coupled with rising populations has left millions without access to acute care. Luckily, there are healthcare companies rising to the challenge with innovative medical technologies and nuanced approaches to how we treat and care for our patients.

  • GlobeNewswire3 months ago

    Novavax Reports Fourth Quarter and Year-End 2018 Financial Results

    GAITHERSBURG, Md., March 18, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months.

  • ACCESSWIRE3 months ago

    These Four Healthcare Stocks Are Making Moves on Wednesday

    CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The healthcare stock market has managed to attract significant attention in the initial months of 2019 as a result of healthcare companies demonstrating to investors and consumers their commitment to the future of the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Advaxis Inc (ADXS), and MannKind Corporation (MNKD) are 4 healthcare companies raising the bar on Wednesday. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care.

  • ACCESSWIRE4 months ago

    These Four Healthcare Stocks are Surging with Potential

    CORAL GABLES, FL / ACCESSWIRE / March 12, 2019 / The healthcare stock market is comprised of innovative companies working diligently to design, manufacture, and commercialize state-of-the-art tech-driven solutions for the healthcare industry. It is the responsibility of healthcare companies to meet the oncoming challenges presented by infectious diseases and ailments, and so long as they can meet these requirements, the healthcare sector could generate market excitement. Premier Health Group (OTC:PHGRF) (CSE:PHGI), ENDRA Life Sciences Inc (NDRA), Novavax Inc (NVAX), and Aevi Genomic Medicine Inc (GNMX) are 4 healthcare companies raising the bar on Tuesday.

  • GlobeNewswire4 months ago

    Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial Results on March 18, 2019

    GAITHERSBURG, Md., March 11, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter 2018 financial and operating results prior to U.S. financial.

  • ACCESSWIRE4 months ago

    The Device Market That Drove One Company From $2.50 to $65 Has a New Entrant

    The move to get patients out of doctors offices and hospitals quickly using virtual care and remote monitoring is underway. Technology is enabling the switch, and few sub-sectors have benefited more than remote cardiac care. Companies like Biotelemetry (BEAT) have grown by leaps and bounds in the last few years as their proprietary remote cardiac monitoring devices have gained traction.

  • ACCESSWIRE4 months ago

    Four Healthcare Stocks Seeing Gains On Wednesday

    At the end of the day, our health is our key priority, and it is the responsibility of the healthcare industry to meet the growing demands of consumers as more diseases are discovered. Interestingly enough, amid this responsibly lies the opportunity for healthcare companies to unlock lucrative potential and attract investors to the space. If companies in the healthcare sector continue to take creative approaches to design drug treatments and care solutions, this will, in turn, improve the lives of consumers, thus catalyzing significant investor interest in the sector.

  • GlobeNewswire4 months ago

    Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax™ for Prevention of RSV Disease in Infants via Maternal Immunization

    Trial did not meet primary objective of prevention of medically significant RSV LRTITrial did show efficacy against secondary objective (RSV LRTI hospitalization); first RSV.

  • GlobeNewswire4 months ago

    Research Report Identifies Novavax, Zillow Group, Broadridge Financial Solutions, Summit Midstream Partners, LP, Primoris Services, and RE/MAX with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE5 months ago

    4 Healthcare Stocks Looking For A Healthy Start On Monday (1/28/19)

    With headlines popping up left and right, news surrounding these innovative companies in the healthcare industry has worked to attract investors looking for potential opportunities in the space. As an industry predicated on improving the quality of life for consumers, Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Trevena Inc (TRVN), and Teladoc Health Inc (TDOC) represent four healthcare companies determined to invest in the betterment of the global health market. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with state-of-the-art technologies used throughout the healthcare industry to create the best-possible care solutions for their growing patient network.

  • ACCESSWIRE5 months ago

    A Biotech Play You Can't Afford To Miss

    HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotechnology companies have seen a ton of interest from Big Pharma so far in 2019. While it's not easy to project who may be next, there are several biotech ...

  • ACCESSWIRE5 months ago

    Best Bottom Bouncing Opportunities

    HENDERSON, NV / ACCESSWIRE / January 17, 2019 / Below are some incredible opportunities in the market today. Gopher Protocol Inc. (GOPH) , is an absolutely fascinating company that was trading has a 52-week ...

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: Novavax and Allogene Therapeutics

    NEW YORK, NY / ACCESSWIRE / January 14, 2019 / U.S. equities posted strong weekly gains, however, stock closed lower for the day on Friday on concerns over an ongoing U.S. government shutdown and worries ...

  • ACCESSWIRE6 months ago

    These 4 Healthcare Stocks Are Making Moves

    CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Synergy Pharmaceuticals Inc (SGYP), Novavax Inc (NVAX), and Epizyme Inc (EPZM) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI) opened Friday with the Company's shares trading at $0.63 per share, well above the $0.53 close back in October, as well as steadily ahead of $0.59 per share price point from early last month.

  • ACCESSWIRE6 months ago

    Biotech Stocks Set to Start 2019 Off with a Bang

    HENDERSON, NV / ACCESSWIRE / January 4, 2019 / Biotech companies could be in store for a big 2019, and investors are starting to take notice. The stocks we are highlighting today all look poised for a ...

  • GlobeNewswire6 months ago

    Novavax Announces Positive Phase 2 NanoFlu Results in Older Adults

    The trial compared the safety and immune responses of various quadrivalent formulations of NanoFlu, with or without Novavax’ Matrix-M™ adjuvant, with two U.S.-licensed influenza vaccines in 1,375 healthy adults 65 years of age and older.

  • GlobeNewswire6 months ago

    Novavax to Present at the 37th Annual J.P. Morgan Healthcare Conference

    GAITHERSBURG, Md., Jan. 02, 2019 -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference. Presentation details.